Les Centres GHESKIO CRS (30022)
Welcome,         Profile    Billing    Logout  
 9 Trials 
13 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Severe, Patrice
NCT04311957: Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Not yet recruiting
4
386
RoW
Continuation of boosted PI, B/F/TAF
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Brigham and Women's Hospital, Harvard Medical School, Analysis Group, Inc., Weill Medical College of Cornell University
HIV-1-infection, Antiretroviral Therapy
05/22
11/22
CRUSH-TB, NCT05766267: Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2/3
288
Canada, US, RoW
Rifabutin, Delamanid, Deltyba, Bedaquiline, Sirturo, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Centers for Disease Control and Prevention, Tuberculosis Trials Consortium
Tuberculosis, Pulmonary, Tuberculosis Infection
12/26
12/27
PRESCIENT, NCT05556746: Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Recruiting
2
156
RoW
Bedaquiline, Clofazimine, Pyrazinamide, Delamanid, Rifampin, Isoniazid, Ethambutol
Brigham and Women's Hospital, University of Cape Town, Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, University of Stellenbosch, University of California, Los Angeles, Harvard School of Public Health (HSPH)
Tuberculosis, Pulmonary, HIV
08/25
01/27
Riviere, Cynthia
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Active, not recruiting
3
5832
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
01/27
01/27
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
08/25
03/26
NCT02906007: Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

Active, not recruiting
1/2
54
RoW
Bedaquiline, BDQ
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV
02/24
08/25
NCT02140255: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Recruiting
1/2
1120
US, RoW
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, DTG, VRC07-523LS
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
HIV Infection
01/28
12/31
Pierre, Samuel
NCT04311957: Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Not yet recruiting
4
386
RoW
Continuation of boosted PI, B/F/TAF
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Brigham and Women's Hospital, Harvard Medical School, Analysis Group, Inc., Weill Medical College of Cornell University
HIV-1-infection, Antiretroviral Therapy
05/22
11/22
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
CRUSH-TB, NCT05766267: Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2/3
288
Canada, US, RoW
Rifabutin, Delamanid, Deltyba, Bedaquiline, Sirturo, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Centers for Disease Control and Prevention, Tuberculosis Trials Consortium
Tuberculosis, Pulmonary, Tuberculosis Infection
12/26
12/27
NCT04311502: Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Completed
2
104
RoW
Clofazimine (CFZ), Rifapentine (RPT), Isoniazid (INH), Pyrazinamide (PZA), Ethambutol (EMB), Rifampicin (RIF), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
06/24
06/24
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Suspended
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
03/26
03/27
NCT02906007: Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

Active, not recruiting
1/2
54
RoW
Bedaquiline, BDQ
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV
02/24
08/25
Rouzier, Vanessa
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Severe, Patrice
NCT04311957: Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Not yet recruiting
4
386
RoW
Continuation of boosted PI, B/F/TAF
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Brigham and Women's Hospital, Harvard Medical School, Analysis Group, Inc., Weill Medical College of Cornell University
HIV-1-infection, Antiretroviral Therapy
05/22
11/22
CRUSH-TB, NCT05766267: Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2/3
288
Canada, US, RoW
Rifabutin, Delamanid, Deltyba, Bedaquiline, Sirturo, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Centers for Disease Control and Prevention, Tuberculosis Trials Consortium
Tuberculosis, Pulmonary, Tuberculosis Infection
12/26
12/27
PRESCIENT, NCT05556746: Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Recruiting
2
156
RoW
Bedaquiline, Clofazimine, Pyrazinamide, Delamanid, Rifampin, Isoniazid, Ethambutol
Brigham and Women's Hospital, University of Cape Town, Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, University of Stellenbosch, University of California, Los Angeles, Harvard School of Public Health (HSPH)
Tuberculosis, Pulmonary, HIV
08/25
01/27
Riviere, Cynthia
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Active, not recruiting
3
5832
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
01/27
01/27
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
08/25
03/26
NCT02906007: Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

Active, not recruiting
1/2
54
RoW
Bedaquiline, BDQ
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV
02/24
08/25
NCT02140255: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Recruiting
1/2
1120
US, RoW
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, DTG, VRC07-523LS
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
HIV Infection
01/28
12/31
Pierre, Samuel
NCT04311957: Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Not yet recruiting
4
386
RoW
Continuation of boosted PI, B/F/TAF
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Brigham and Women's Hospital, Harvard Medical School, Analysis Group, Inc., Weill Medical College of Cornell University
HIV-1-infection, Antiretroviral Therapy
05/22
11/22
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
CRUSH-TB, NCT05766267: Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2/3
288
Canada, US, RoW
Rifabutin, Delamanid, Deltyba, Bedaquiline, Sirturo, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Centers for Disease Control and Prevention, Tuberculosis Trials Consortium
Tuberculosis, Pulmonary, Tuberculosis Infection
12/26
12/27
NCT04311502: Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Completed
2
104
RoW
Clofazimine (CFZ), Rifapentine (RPT), Isoniazid (INH), Pyrazinamide (PZA), Ethambutol (EMB), Rifampicin (RIF), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
06/24
06/24
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Suspended
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
03/26
03/27
NCT02906007: Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

Active, not recruiting
1/2
54
RoW
Bedaquiline, BDQ
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV
02/24
08/25
Rouzier, Vanessa
No trials found

Download Options